Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration

Area of Science:

• Cardiovascular Medicine
• Hematology
• Pharmacology

Background:

• Unstable angina (UA) is characterized by elevated plasma levels of tissue factor (TF), tissue factor pathway inhibitor (TFPI), and monocyte procoagulant activity (PCA).
• In vitro studies indicate heparin can inhibit TF production and cytokine gene expression in stimulated monocytes.
• In vivo heparin administration has shown promise in reducing ischemic events in UA patients.

Purpose of the Study:

• To investigate the effects of subcutaneous heparin administration on TF, TFPI plasma levels, and monocyte PCA in patients with refractory unstable angina.
• To assess the changes in these markers before and during heparin treatment.

Main Methods:

• A study involving 28 refractory UA patients.
• Subcutaneous heparin administration (thrice daily, weight- and PTT-adjusted for 3 days, followed by 5000 IU x 3 for 5 days).
• Measurement of TF, TFPI plasma levels, and monocyte PCA at baseline, during treatment, and post-treatment.

Main Results:

• After 2-day treatment, TF and TFPI levels decreased compared to baseline.
• Four hours post-heparin injection, TF levels decreased significantly (-32.5%), while TFPI levels increased significantly (+67%).
• After 7-day treatment, TF and TFPI levels were significantly lower than pre-treatment values. On day 8, TF and monocyte PCA decreased significantly (-38% and -55%), and TFPI increased (+70%).

Conclusions:

• Heparin treatment is associated with a significant reduction in elevated TF plasma levels and monocyte procoagulant activity in UA patients.
• These effects of heparin may contribute to its antithrombotic and anti-inflammatory properties in UA.
• Further research could elucidate the precise mechanisms and clinical implications of these findings.